Previous 10 | Next 10 |
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada PR Newswire Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and A...
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and Chief Executive...
2023-12-07 15:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ...
2023-11-13 18:50:25 ET DURECT Corporation (DRRX) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebo...
2023-11-13 16:08:14 ET More on DURECT DURECT: Reading Into AHFIRM Mortality Rates HC Wainwright downgrades DURECT to neutral, removes price target Durect plummets as lead asset fails in mid-stage trial for liver disorder Seeking Alpha’s Quant Rating on...
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update PR Newswire - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of lars...
2023-11-13 07:12:29 ET Summary On Nov 7, DURECT announced topline results from AHFIRM, a phase 2 randomized, placebo-controlled trial studying larsucosterol for severe alcohol-associated hepatitis (AH). The trial did not meet the primary endpoint, i.e. statistically-significant be...
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of ...
2023-11-08 14:30:27 ET More on DURECT Durect plummets as lead asset fails in mid-stage trial for liver disorder Northland sees DURECT's upcoming data as "major" catalyst for stock (update) Seeking Alpha’s Quant Rating on DURECT Historical earnings data...
2023-11-08 13:40:12 ET Gainers: Tenon Medical ( TNON ) +37% . Blade Air Mobility ( BLDE ) +32% . Novo Integrated Sciences ( NVOS ) +29%. Therealreal ( REAL ) +27% . ShiftPixy ( PIXY ) +20% . American Public Education ( APEI )...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...